Eterna Therapeutics Inc (ERNA)
$4.57
$-0.17
(-3.48%)
As on 28-Aug-2026 16:00EDT
Market cap
$5 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
1.7
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-3.2 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-0.3
-
Debt to Equity
0
-
Book Value
$5.9
-
EPS
$-15.3
-
Face value
--
-
Shares outstanding
1,166,333
10 Years Aggregate
CFO
$-78.86 Mln
EBITDA
$39.46 Mln
Net Profit
$-175.21 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Eterna Therapeutics Inc (ERNA)
| -84.8 | 16.6 | -59.0 | -86.8 | -82.7 | -74.6 | -46.3 |
|
BSE Sensex*
| -9.1 | -1.2 | 2.9 | -3.6 | 5.7 | 6.2 | 10.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
|---|---|---|---|
|
Eterna Therapeutics Inc (ERNA)
| -72.8 | -83.4 | -44.1 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Eterna Therapeutics Inc (ERNA)
|
4.6 | 5.3 | 0.0 | -12.3 | -- | -437.7 | -- | 1.7 |
| 84.9 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 247.9 | 16,261.1 | 1,054.4 | 755.9 | 5.7 | -- | 19 | 9.8 | |
| 72.1 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 54.5 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 105.4 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 351.5 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 533.8 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 600.7 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 344.8 | 9,625.4 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 |
Shareholding Pattern
View DetailsAbout Eterna Therapeutics Inc (ERNA)
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's lead product is ERNA-101, an allogenic... pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts. Read more
-
Principal Financial & Accounting Officer and Senior VP of Finance
Ms. Sandra M. Gurrola
-
Principal Financial & Accounting Officer and Senior VP of Finance
Ms. Sandra M. Gurrola
-
Headquarters
Cambridge, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Eterna Therapeutics Inc (ERNA)
What is the current share price of Eterna Therapeutics Inc (ERNA) Today?
The share price of Eterna Therapeutics Inc (ERNA) is $4.57 (NASDAQ) as of 28-Aug-2026 16:00 EDT. Eterna Therapeutics Inc (ERNA) has given a return of -82.68% in the last 3 years.
What is the current PB & PE ratio of Eterna Therapeutics Inc (ERNA)?
Since, TTM earnings of Eterna Therapeutics Inc (ERNA) is negative, P/E ratio is not available.
The P/B ratio of Eterna Therapeutics Inc (ERNA) is 1.70 times as on 28-Aug-2026, a 67 discount to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-0.03 |
0.16 |
2024 |
-0.02 |
0.59 |
2023 |
-0.03 |
0.29 |
2022 |
-0.04 |
0.08 |
2021 |
-0.01 |
0.03 |
What is the 52 Week High and Low of Eterna Therapeutics Inc (ERNA)?
The 52-week high and low of Eterna Therapeutics Inc (ERNA) are Rs 96.19 and Rs 3.18 as of 31-Aug-2026.
What is the market cap of Eterna Therapeutics Inc (ERNA)?
Eterna Therapeutics Inc (ERNA) has a market capitalisation of $ 5 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Eterna Therapeutics Inc (ERNA)?
Before investing in Eterna Therapeutics Inc (ERNA), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.